Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, ...

Compared with those assigned to aspirin, patients assigned to a P2Y12 inhibitor had a lower net composite of adverse cardiac and cerebrovascular events. HealthDay News — For patients who undergo ...

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, ...

Data on CAY001, a First-in-Class, Polyphosphate (polyP)-Based Therapy, Show Promise in Bypassing P2Y12 Inhibition to Restore Normal Clotting Function These early data are promising as they demonstrate ...

NEW ORLEANS — Two new studies from Asia provide more evidence that extended monotherapy with clopidogrel (Plavix, Sanofi) or another P2Y12 inhibitor antiplatelet, rather than either dual antiplatelet ...

Please provide your email address to receive an email when new articles are posted on . P2Y12 monotherapy after PCI was not as protective from ischemic events vs. DAPT with aspirin. Monotherapy did ...

Two new Asian studies have shown that short durations of dual antiplatelet therapy (DAPT) followed by longer treatment with P2Y12 inhibitor monotherapy alone may be a safe and effective regimen for ...

Madrid, Spain – 31 August 2025: Noninferiority was not demonstrated for death and ischaemic events between P2Y12 inhibitor monotherapy and dual antiplatelet therapy (DAPT) given for 12 months after ...

P2Y12 inhibitors like ticagrelor and clopidogrel provide a 23% lower risk of heart-related death, heart attack or stroke compared to aspirin ...

NEW ORLEANS, LA—A single subcutaneous injection of a novel, small-molecule glycoprotein IIb/IIIa inhibitor administered at first medical contact in patients with suspected STEMI improves the patency ...